Results 11 to 20 of about 319,900 (371)

Sleep and vaccine administration time as factors influencing vaccine immunogenicity [PDF]

Kosin Medical Journal, 2022
The immunogenicity of vaccines is affected by host, external, environmental, and vaccine factors; in addition, sleep or circadian rhythms may also have effects.
Eun Seok Kim, Chi Eun Oh
doaj   +1 more source

Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products. [PDF]

Front Immunol
Chimeric antigen receptor-engineered T cell therapies (CAR-T) are becoming powerful immunotherapeutic tools for treating malignancies, especially hematological malignancies.
Alfar HR, Chen C, Lachacz E, Tang W, Zhang Y.   +4 more
europepmc   +2 more sources

Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine

Biomaterials Research, 2023
Tissue-engineered decellularized extracellular matrix (ECM) scaffolds hold great potential to address the donor shortage as well as immunologic rejection attributed to cells in conventional tissue/organ transplantation.
Mohammadreza Kasravi, Armin Ahmadi, Amirhesam Babajani, Radman Mazloomnejad, Mohammad Reza Hatamnejad, Siavash Shariatzadeh, S. Bahrami, H. Niknejad   +7 more
semanticscholar   +1 more source

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age.
R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, David Cooper, T. Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +25 more
semanticscholar   +1 more source

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations

Frontiers in Medicine, 2022
Cell and Gene Therapy Products (CGT), regulated as Advanced Therapy Medicinal Products (ATMP) in the European Union (EU), represent a novel and varied group of biotherapeutics developed to treat specific conditions for which there are limited or no ...
Laura I. Salazar-Fontana, Laura I. Salazar-Fontana, Laura I. Salazar-Fontana   +2 more
doaj   +1 more source

Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics

Experimental and Molecular Medicine, 2023
Several studies have utilized a lipid nanoparticle delivery system to enhance the effectiveness of mRNA therapeutics and vaccines. However, these nanoparticles are recognized as foreign materials by the body and stimulate innate immunity, which in turn ...
Yeji Lee, Michaela Jeong, Jeongeun Park, Hyein Jung, Hyukjin Lee   +4 more
semanticscholar   +1 more source

Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells

Scientific Reports, 2021
The major histocompatibility complex II (HLA-II) facilitates the presentation of antigen-derived peptides to CD4+ T-cells. Antigen presentation is not only affected by peptide processing and intracellular trafficking, but also by mechanisms that govern ...
A. Casasola-LaMacchia, M. S. Ritorto, R. J. Seward, N. Ahyi-Amendah, A. Ciarla, T. P. Hickling, H. Neubert   +6 more
doaj   +1 more source

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Annals of the Rheumatic Diseases, 2021
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, M. Zisapel, O. Elalouf, I. Kaufman, R. Meidan, A. Broyde, A. Polachek, J. Wollman, I. Litinsky, K. Meridor, H. Nochomovitz, Adi Silberman, D. Rosenberg, J. Feld, A. Haddad, Tal Gazzit, M. Elias, N. Higazi, F. Kharouf, G. Shefer, O. Sharon, S. Pel, S. Nevo, O. Elkayam   +28 more
semanticscholar   +1 more source

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.

Journal of the American Medical Association (JAMA), 2021
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Immunocompromised individuals have been excluded from studies of SARS-CoV-2 messenger RNA (mRNA) vaccines.
B. Boyarsky, William Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik‐Wang   +6 more
semanticscholar   +1 more source

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.
E. Walsh, R. Frenck, A. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. Mulligan, R. Bailey, K. Swanson, Ping Li, K. Koury, W. Kalina, David Cooper, Camila R. Fontes-Garfias, P. Shi, Ö. Türeci, Kristin Tompkins, K. Lyke, V. Raabe, P. Dormitzer, K. Jansen, U. Şahin, W. Gruber   +24 more
semanticscholar   +1 more source